Mar
27
Eli Lilly has received FDA approval for a combo pill called Symbyax to be used for the treatment of treatment-resistant depression.
Symbyax, which combines the ingredients of the antipsychotic Zyprexa (olanzapine) with the antidepressant Prozac (fluoxetine), is approved for patients with major depression who have not responded to two separate trials of different antidepressants.
It was originally approved by the FDA in
Read the rest of this entry
